Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand

Table 4 Results of cost-utility analyses

Policy	Life expectancy (years)	Total lifetime cost (THB)	Total lifetime QALYs	Incremental costs (THB)	QALY gained	Interpretation
Base-case analysis (women age ≥ 25 years, screening age 25–65 years)
No screening	57.0	47 651	23.49
Clinician-collected samples for cytology test (Pap smear)	57.2	40 124	23.54	-7527	0.05	cost-saving^a
Clinician-collected samples for HPV DNA testing	57.2	38 850	23.55	-1273	0.001	cost-saving^b
Self- and clinician-collected samples for HPV DNA testing	57.3	33 052	23.58	-5799	0.03	cost-saving^c
Scenario analysis (women age ≥ 30 years, screening age 30–65 years)
No screening	52.2	55 993	22.36
Clinician-collected samples for cytology test (Pap smear)	52.4	47 954	22.41	-8039	0.05	cost-saving^a
Clinician-collected samples for HPV DNA testing	52.4	46 803	22.42	-1151	0.001	cost-saving^b
Self- and clinician-collected samples for HPV DNA testing	52.5	41 757	22.45	-6045	0.03	cost-saving^c

^a Compared to no screening
^b Compared to clinician-collected samples for cytology test
^c Compared to clinician-collected-samples-only for HPV DNA testing
HPV DNA, human papillomavirus deoxyribonucleic acid; QALY, quality-adjusted life-year; THB, Thai baht

ISSN: 1471-2458